Roche goes 0-2 in the high-stakes race to get a TIGIT through PhIII and onto the market
Roche has racked up its second straight Phase III fail for its TIGIT tiragolumab, flagging a flop on the progression-free survival co-primary endpoint for the drug combined with Tecentriq as a first-line treatment for PD-L1 high patients suffering from non-small cell lung cancer.
The other co-primary endpoint in the SKYSCRAPER-01 study on overall survival hasn’t reached the readout phase yet. But this time around Roche execs are waiting to see if it just might hit positive after seeing numerical gains for both endpoints.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.